covid 19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: First intervention group: Receiving Remdesivir (Ronak Daru Pharmaceutical Company) with a loading dose of 200 mg on the first day and then a daily dose of 100 mg by intravenous injecti
Sponsors
Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Hospitalized patients suspected to Covid19 infection SpO2 less than 93% The presence of respiratory symptoms (including shortness of breath, pain and pressure in the chest) older than 40 years
Exclusion criteria
Exclusion criteria: Dissatisfaction with participating in the study History of severe renal failure History of allergies to interferon or remdesivir History of severe liver failure Pregnancy Lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of hospitalization. Timepoint: 7 -14 days. Method of measurement: Based on patient file information. | — |
Secondary
| Measure | Time frame |
|---|---|
| The duration of recovery or the duration of entry into the disease stage. Timepoint: 7-14 days. Method of measurement: Based on patient file information.;Survival rate of 28 days from the time of hospitalization. Timepoint: 28 days after starting the study. Method of measurement: Interview with the patient or her family.;The amount of arterial oxygen saturation. Timepoint: Daily. Method of measurement: Using a device to measure the percentage of oxygen saturation.;Frequency of transfer to intensive care unit. Timepoint: Daily. Method of measurement: Under supervision. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactForouzan Ahmadpour
Khoram-Abad University of Medical Sciences
Outcome results
None listed